From NBCUniversal: 2024-10-16 10:21:51

The FDA has halted Novavax’s application for a combination Covid and flu shot and standalone flu vaccine due to nerve damage reported in a patient. Novavax stock fell 20% as the clinical hold delays phase three trials. The biotech company is working with the FDA to resolve the issue and aims to start trials soon. Novavax’s protein-based Covid vaccine offers an alternative to mRNA shots from Pfizer and Moderna.



Read more at NBCUniversal: Novavax shares plunge as company says FDA put hold on two shots